Trding , I try to educate myself about CAR- T treatment since a long time now , and this is an excellent article ...

It is a very dangerous treatment , mostly done in the hospital by ICU or in ICU and still I believe about 15% mortality , plus some problems persisting especially with brain activity in some patients ,
But it is given to patients without other choice...

We see,

--multi organ failure ..
--drop of blood pressure , severe..
--neurotoxicity..
--violent seizures..

Now it is believe that all that , or most all are due to..

" Cytokine Release Syndrome "....It is a damage of Immune system.
We see that in about 50% of patients....

First T-cells are activated , they recruiting cytokines, cytokines then recruit more immune cells.

During our last CC someone was asking for some time what they think about CAR-T treatment , and how this might affect Leronlimab..
Dr Patterson came to answer , and what he basically said is , that Leronlimab will help here also all those immune abnormalities ( I am paraphrasing here )

So , so far we know about leronlimab with other cancer treatment ...

---With Chemotherapy , preventing developing resistance , and make chemotherapy working about 250% stronger ( per Dr Pestell )
--in immune therapy prevent developing resistance , helping as a immune therapy drug , and preventing developing autoimmune reaction..per Dr Patterson
-- most probably in CAR-T treatment helping to prevent/improve Cytokine Release Syndrome ..



All as always IMO.